7 BD HAUSSMANN, PARIS, I0
Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis
Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
Annouces Results of its May 11, 2026 Annual General Meeting
Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
Annual Ordinary and Extraordinary General Meeting of May 11, 2026
Material disclosure
Presents Third Quarter 2025 Financial Results
Presents First Half 2025 Financial Results
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(4)
No filings found
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Prospectus filed pursuant to Rule 424(b)(7)
Free Writing Prospectus
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis